Several factors have combined to transform the role of licensing in the pharmaceutical industry - the reconfiguration of the value chain, ongoing global consolidation and M&A and plummeting R&D productivity. In response, licensing has moved away from its roots as a transaction for intellectual property rights, emerging as a key value driver. Industry leaders now recognise licensing as a strategic mechanism through which they can achieve their corporate objectives. The Pharmaceutical Licensing Outlook, a new management report from Business Insights, identifies and examines current best practice in licensing. Using a blend of market analysis, case studies and executive interviews, the author provides a comprehensive guide to how best to maximize the returns on licensing activity. Equally valuable for pharmaceutical companies, biotechnology companies and technology providers, this groundbreaking report offers both practical and strategic analysis, including a detailed evaluation of successful deal-making.
ISBN 1-84296-209-4
Published: August 2002 - Global. |
